A5100671433- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Colorectal Cancer Treatments and Studies
- BRCA gene mutations in cancer
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Estrogen and related hormone effects
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- PI3K/AKT/mTOR signaling in cancer
- Radiopharmaceutical Chemistry and Applications
- Peptidase Inhibition and Analysis
- Breast Lesions and Carcinomas
- Chemotherapy-related skin toxicity
- Genetic factors in colorectal cancer
- Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
Hospital General Universitario Gregorio Marañón
2016-2025
GEICAM – Spanish Breast Cancer Group
2016-2025
Centro de Investigación Biomédica en Red de Cáncer
2017-2025
Instituto de Salud Carlos III
2010-2024
Yonsei University
2024
Universidad Complutense de Madrid
2015-2024
Centre for Biomedical Network Research on Rare Diseases
2020-2023
Singapore-MIT Alliance for Research and Technology
2023
Sonnenhalde (Switzerland)
2023
Clinica Universidad de Navarra
2018-2023
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated cardiac toxicity. We wanted to evaluate efficacy and safety a new nonanthracycline regimen trastuzumab.We randomly assigned 3222 women HER2-positive early-stage cancer receive doxorubicin cyclophosphamide followed by docetaxel every 3 weeks (AC-T), same plus 52 trastuzumab (AC-T trastuzumab), or carboplatin (TCH). The primary...
A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than alone in the initial treatment of postmenopausal women estrogen-receptor (ER)–positive, human epidermal growth factor receptor (HER2)–negative advanced breast cancer. We performed a 3 designed to confirm and expand efficacy safety data for this indication.
We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil (FAC) as adjuvant chemotherapy for operable node-positive breast cancer.
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy the setting. Patients and Methods randomly assigned at a two-to-one ratio placebo fulvestrant. The primary end point was locally assessed progression-free survival. Secondary points included overall survival, response rate,...
In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than alone in postmenopausal patients hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Here we report the results protocol-specified second interim overall survival.
Purpose We compared fulvestrant 500 mg regimen with the approved dose of 250 per month for treatment postmenopausal women estrogen receptor–positive advanced breast cancer who experienced progression after prior endocrine therapy. Patients and Methods Comparison Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) is a double-blind, parallel-group, multicenter, phase III study. were randomly assigned to (500 intramuscularly [IM] on day 0, then IM days 14 28 every thereafter) days....
Abstract Background: Evaluation of the long-term benefit biologically-based regimens trastuzumab in early breast cancer population, and optimization integration to maximize efficacy minimize cardiac toxicity.Material Methods: We randomized HER2-positive (FISH+) patients with axillary lymph node positive or high risk negative, either standard AC (60/600 mg/m2 q3wk x4) followed by T (100 x 4) two trastuzumab-containing regimens; 1 year TCarbo (75 mg/m2/AUC6 6) year. Patients were prospectively...
Purpose Current immunohistochemical (IHC)-based definitions of luminal A and B breast cancers are imperfect when compared with multigene expression-based assays. In this study, we sought to improve the IHC subtyping by examining pathologic gene expression characteristics genomically defined subtypes. Patients Methods Gene features were collected from primary tumors across five independent cohorts: British Columbia Cancer Agency (BCCA) tamoxifen-treated only, Grupo Español de Investigación en...
Abstract At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). is randomized, phase III, double-blind study of abemaciclib/placebo (150 mg twice daily, continuous) AI (1 anastrozole or 2.5...
Purpose To investigate the prognostic and predictive significance of subtyping node-positive early breast cancer by immunohistochemistry in a clinical trial docetaxel-containing regimen. Methods Pathologic data from central laboratory were available for 1,350 patients (91%) BCIRG 001 docetaxel, doxorubicin, cyclophosphamide (TAC) versus fluorouracil, (FAC) operable cancer. Patients classified tumor characteristics as (1) triple negative (estrogen receptor [ER]–negative, progesterone...
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical molecular features HER2-low BC yet to be elucidated. Here, we collected retrospective clinicopathological PAM50 data from 3,689 patients disease made following observations. First, proportion was higher HR-positive (65.4%) than triple-negative (TNBC, 36.6%). Second, within disease, luminal-related...
Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant currently available standard therapies. However, up to 30% of high-risk clinical and/or pathologic features may recurrence, many in the first few years. Superior treatment options are needed prevent and development metastases for this group patients. Abemaciclib is an oral, continuously dosed, CDK4/6 inhibitor approved advanced (ABC). Efficacy safety abemaciclib ABC supported evaluation...
This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC).Patients (n = 429) were randomly assigned to receive 50 mg/m(2) plus 75 214) or 60 600 215) on day 1, every 3 weeks for up eight cycles.Time progression (TTP; primary end point) time treatment failure (TTF) significantly longer AT than AC (median TTP, 37.3 v 31.9 weeks; log-rank P =.014; median TTF, 25.6 23.7...
Abstract The cellular and molecular basis of stromal cell recruitment, activation crosstalk in carcinomas is poorly understood, limiting the development targeted anti-stromal therapies. In mouse models triple negative breast cancer (TNBC), Hedgehog ligand produced by neoplastic cells reprograms cancer-associated fibroblasts (CAFs) to provide a supportive niche for acquisition chemo-resistant, stem (CSC) phenotype via FGF5 expression production fibrillar collagen. Stromal treatment...
Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) –targeted monoclonal antibodies, trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the properties of with cytotoxic activity DM1. T-DM1 demonstrated encouraging efficacy safety in a phase II study patients previously untreated HER2-positive metastatic breast cancer. Combination showed synergistic cell culture models had acceptable profile Ib study. Methods In MARIANNE study, 1,095...